Drugs and Lactation Database (LactMed(R))-/-ä 2006[]; ä (ä): ä PMID32401463show ga
Favipiravir is an investigational antiviral drug in the US that is being tested for use against the novel coronavirus disease, COVID-19. Information from one patient indicates that milk levels are low with a peak level at about 2 hours. One infant has reportedly been breastfed by a mother receiving favipiravir and pumping her breasts after doses with no adverse effects reported in the infant. Favipiravir has caused liver enzyme abnormalities, gastrointestinal symptoms, and serum uric acid elevations.[1,2] If favipiravir is used in a nursing mother, these parameters should be monitored in the breastfed infant.